Introduction
============

Endogenous glucocorticoid steroid hormones---cortisol in humans and corticosterone in rodents---act to regulate transcriptional pathways in diverse cellular contexts to regulate development, homeostasis, metabolism, cognition and inflammation. Since glucocorticoids have anti-inflammatory and immunosuppressive properties, they are frequently used to treat many inflammatory conditions, from inflammatory arthritis and ulcerative colitis to asthma and skin diseases, while pro-apoptotic properties make them a major component of the treatment of many oncological disorders. Unfortunately, however, long-term and/or high-dose glucocorticoid administration is commonly associated with side effects, from hyperglycaemia, weight gain and hypertension to osteoporosis, depression and decreased immunological function. Furthermore, patients on glucocorticoids can develop reduced glucocorticoid sensitivity and even resistance. Although the prevalence of glucocorticoid resistance is unclear, in part due to poor definitions, some reports suggest up to one-third of patients with asthma \[[@B1]\], RA \[[@B2]\], ulcerative colitis \[[@B3]\] and SLE \[[@B4]\] show altered glucocorticoid sensitivity \[[@B5]\]. Furthermore, 10--30% of patients with acute lymphocytic leukaemia are glucocorticoid resistant, with a higher rate of resistance developing in patients who have had a relapse of leukaemia \[[@B6]\].

The actions of glucocorticoids are predominantly mediated through its receptor, the glucocorticoid receptor (GR). Upon exposure to glucocorticoids, GR undergoes a structural conformational change that drives translocation from the cell cytoplasm into the nucleus. Once in the nucleus, ligand-bound GR is available to interact with regulatory elements in the genome \[[@B7; @B8; @B9; @B10; @B11; @B12]\], where it is known to induce and repress transcription of hundreds of target genes \[[@B12], [@B13]\]. The expression of GR, a DNA-binding transcription factor of the nuclear receptor superfamily, is nearly ubiquitously expressed \[[@B14]\]. Its biological activities result predominately from interactions with chromatin. Chromatin is a complex of DNA with DNA packaging proteins called nucleosomes. Nucleosomes are made up of histone proteins, which act to compact the length of DNA into the nucleus. The availability of binding sites for GR in the DNA necessitates engagement with chromatin to access the underlying DNA concealed by nucleosomes. Through mechanisms that alter chromatin structure via histone modifications, and structural remodelling, as well as DNA methylation, the accessibility of the DNA sequence can be modified \[[@B15]\]. These factors do not alter the DNA sequence, but can provide epigenetic memory of transcriptional states \[[@B16]\], that is, non-genetic mechanisms that are heritable across cell division and generations. In this review we discuss the complexity of glucocorticoid signalling, in the context of GR interactions with chromatin, and the factors that contribute to steroid sensitivity, resistance and unwanted side effects.

Physiological and pathological patterns of glucocorticoid secretion
===================================================================

The secretion of glucocorticoid hormones from the adrenal gland is under the control of adrenocorticotropic hormone (ACTH) from the anterior pituitary and corticotropin-releasing hormone (CRH) from the hypothalamus. Additionally, the circulating level of cortisol is regulated through its negative feedback activity on both ACTH and CRH release \[[@B17]\]. These regulatory loops act to maintain normal physiological levels of hormone \[[@B17]\]. The pattern of cortisol secretion is classically circadian, with peak secretion early in the morning in anticipation of waking-related activities ([Fig. 1](#F1){ref-type="fig"}). This circadian pattern, however, is actually made up from an underlying ultradian pattern of hormone secretion, with the largest pulses of secretion occurring early in the morning ([Fig. 1](#F1){ref-type="fig"}). This ultradian pattern is evolutionarily conserved across mammals, implicating pulsatility as an important feature of glucocorticoid signalling \[[@B18], [@B19]\]. F[ig.]{.smallcaps} 1Glucocorticoid pulsatility drives transient activation of GR-responsive genes. Murine serum corticosteroid (cort) levels rise in anticipation of the active phase. Hormone levels follow a circadian pattern, although the underlying pattern of hormone secretion is ultradian, where glucocorticoids are released approximately every hour. During a pulse, exposure to hormone drives GR translocation into the nucleus, where it binds to genomic elements to drive transcription. Hormone troughs result in GR dissociation from chromatin, releasing the receptor into the nucleoplasm ready to initiate transcription during further rises in hormone levels. The dynamics of the receptor and hormone secretion patterns allow rapid response to rapidly changing cellular and physiological conditions.

The pattern of glucocorticoid ultradian pulsatility is highly variable in frequency and amplitude. Studies in the rat show sex-specific differences, and both genetic and epigenetic modification of ultradian pattern and glucocorticoid response to stress \[[@B17], [@B18]\]. Altered patterns of glucocorticoid secretion also occur in response not only to acute stressors, but also to chronic stress states such as obstructive sleep apnoea in man \[[@B20]\], and of particular importance for this review, immune-mediated disease both in man and in experimental animal models \[[@B21], [@B22]\]. The significance of the hypothalamic-pituitary-adrenal (HPA) axis--immune interaction has been appreciated for many years \[[@B23]\]. As inflammation drives increased production of anti-inflammatory glucocorticoids, the HPA--immune axis acts in a classical negative feedback loop \[[@B24]\]. Evidence from animal experiments strongly implicates the HPA axis in regulating inflammation \[[@B25; @B26; @B27]\]. Accordingly, disruption of the HPA axis by adrenalectomy results in increased disease severity in an experimental model of adjuvant-induced arthritis \[[@B27; @B28; @B29]\]. Significantly, dysregulated rhythms of endogenous glucocorticoid secretion are a key characteristic of inflammation-associated chronic activation of the HPA axis, with loss of circadian rhythm \[[@B30]\] and altered ultradian rhythm \[[@B22]\].

There is also evidence that chronic exposure to altered glucocorticoid secretion following chronic stress can result in glucocorticoid resistance \[[@B31], [@B32]\]. Indeed, there is evidence that suggests this can be a feature of RA \[[@B33]\]. It is clear, therefore, that there are dynamic patterns of glucocorticoid secretion that respond to both physiological and pathological states, and suggest that during some of these pathological states the aberrant glucocorticoid secretory pattern could alter glucocorticoid signalling and resistance.

Another situation in which there is an altered pattern of plasma glucocorticoids is found during glucocorticoid therapy---either when it is given therapeutically as an anti-inflammatory or immune modulator, or when it is given as replacement therapy in Addison\'s disease, congenital adrenal hyperplasia or hypopituitarism. Unfortunately, current treatment protocols are unable to reproduce either the normal ultradian pattern of hormone secretion or the pre-awakening circadian rise of hormone secretion, although new delayed-release preparations are being developed that may improve the circadian pattern \[[@B34]\]. There is now considerable evidence that pulsatile changes in plasma glucocorticoid levels result in gene pulsing mediated by transient GR activation \[[@B35], [@B36]\]. Pulsatile patterns therefore exert homeostatic control through GR-dependent transcription regulation that rapidly responds to circulating hormone levels ([Fig. 1](#F1){ref-type="fig"}) \[[@B36], [@B37]\]. Conversely, constant non-oscillatory hormone levels result in continuous transcription, aberrant mRNA accumulation and abnormal protein levels \[[@B36]\]. We suggest that a treatment regimen comprising pulsatile glucocorticoid patterns over a circadian rhythm might confer therapeutic benefits while minimizing undesired side effects.

Genomic actions and cell specificity of GR
==========================================

The organization of DNA in eukaryotic cells as chromatin permits compaction of DNA into the nuclear space. DNA-binding factors, such as GR, must overcome the chromatin barrier to access the underlying DNA sequences in regulatory elements to drive transcription control. Accessibility of chromatin across the genome, however, is highly variable. Recent genome-wide data have shown that active regulatory elements, such as promoters and enhancers, are openly accessible chromatin domains \[[@B38], [@B39]\].

Upon ligand activation, GR acts as a sequence-specific transcription factor, binding to a consensus DNA motif, the glucocorticoid response element (GRE), to drive gene expression \[[@B40]\]. Despite widespread expression, GR regulation of transcriptional programmes is highly cell and tissue specific, binding to distinct genomic loci in different cellular contexts \[[@B10; @B11; @B12]\]. With hundreds of different cell types in complex eukaryotes containing identical genomic content, the selection of specific binding sites in different cells has remained an important question. Chromatin has emerged over the past few decades as a critical player in transcriptional regulation. Control of transcription is thought to occur through altering chromatin structure or epigenetics by mechanisms such as chromatin remodelling, DNA methylation and modifications of histones. Indeed, the accessibility of chromatin has been shown to direct the binding of GR to regulatory elements \[[@B10], [@B11]\]. Importantly, cell-specific GR-binding events are associated with cell-specific regulatory elements marked by accessible chromatin \[[@B10], [@B11]\]. The vast majority of interactions between GR and chromatin have been shown to be predetermined before hormone, that is, GR predominantly binds to the genome at chromatin where the DNA is accessible before hormone and thus independent of hormone action. These observations implicate open chromatin as a major player in GR binding and define the cell-specific landscape of GR action, suggesting the cellular context contributes to the pre-setting of cell-specific hormone action \[[@B11]\].

In addition to the direct actions of GR on DNA, the receptor interacts with a large cohort of other DNA-binding factors \[[@B41]\]. Known cooperative protein--protein interactions include nuclear factor 1 (NF1), CCAAT/enhancer-binding proteins (C/EBP) and octamer transcription factors \[[@B42; @B43; @B44]\]. Through interacting with these accessory factors, GR-dependent transcription is thought to be dynamic and variable, including cell-specific interactions with accessory factors ([Fig. 2](#F2){ref-type="fig"}A) \[[@B11]\]. Therefore the regulation of cell-specific genes by glucocorticoids is dependent on the expression and activity of interacting partners. These interactions allow diversity in regulatory control over activated genes and also mean that alterations in accessory factor activity could modify the sensitivity and resistance to hormone action. F[ig.]{.smallcaps} 2Cell- and gene-specific actions of GR. (**A**) Chromatin accessibility is a major determinant of receptor binding to chromatin. Active genes are shown to have accessible DNA and acetylated (Ac) histones. Genes induced by GR require homodimers that bind directly to DNA at GREs. Hormone-dependent gene repression is mediated by homomeric GR protein--protein interactions with other transcription factors such as AP1. (**B**) Transcription output in the presence of constant hormone is kinetically diverse. Induced and repressed genes can undergo phases of up- and down-regulation. Induced genes can be continuously (blue) or transiently (green) induced, or induced to a maintained plateau state (red). Similarly, repressed genes can be continuously (black) or transiently (purple) repressed, or repressed in a plateau state over time (orange). Lines represent classes of genes. The kinetics of transcription is therefore gene specific. Cort: corticosterone/cortisol, Ac: acetylation.

Temporal dynamics of gene regulation by the GR
==============================================

GR is known to positively and negatively regulate transcription \[[@B12], [@B13], [@B45]\]. GR-dependent induction and repression of genes play critical roles in metabolic, circadian and inflammatory signalling networks. Inductive actions of homodimeric GR are mediated through direct binding to DNA at GREs \[[@B46], [@B47]\]. Upon DNA binding, GR promotes the recruitment of chromatin-modifying co-factors and the transcriptional machinery, including RNA polymerase II (Pol II) to drive transcription \[[@B48]\]. The recruitment of co-factors such as Brg1 and the histone acetyltransferase (HAT) CBP/p300 by GR alters chromatin structure to an accessible state poised for gene activation ([Fig. 2](#F2){ref-type="fig"}) \[[@B49], [@B50]\]. For instance, the chromatin-remodelling activity of Brg1 is thought to alter the positioning and composition of nucleosomes, while HATs acetylate the histones H3 and H4 \[[@B51; @B52; @B53]\]. Both mechanisms are thought to alter the contacts between nucleosomes and DNA, exposing the DNA to regulatory factor binding \[[@B54], [@B55]\].

The binding of GR to chromatin and the hormone-dependent remodelling of chromatin is highly dynamic. Using fluorescently tagged receptor coupled with photobleaching experiments to monitor recovery times, GR was found to rapidly cycle chromatin on and off in living cells in seconds to minutes \[[@B56], [@B57]\]. In contrast to the classic model where binding of transcription factors to DNA is represented by stable complexes, the current model suggests transient transcription factor binding to chromatin \[[@B37]\]. Here, GR rapidly engages and disengages the chromatin template, during which Brg1-dependent chromatin remodelling concomitantly undergoes dynamic exchange \[[@B58], [@B59]\].

In addition to the rapid exchange of GR on chromatin, a slower cyclical activity is imposed on GR by the ultradian rhythm of ligand exposure, a phasic GR action regulated by the deterministic mechanism of the ligand pulse pattern \[[@B60]\]. The phasic action of GR is evident as cyclical shifts in the net equilibrium of GR at regulatory elements towards a bound state \[[@B61]\]. Precisely tracking the rhythm of pulsatile hormone and cyclical GR activity are cyclical changes in recruitment of the HAT complex CBP/P300. Phasic CBP/P300 recruitment results in rapid and reversible increases in histone acetylation at regulatory regions in glucocorticoid-target genes, again in phase with the ultradian hormone pattern \[[@B61], [@B62]\]. As histone acetylation is associated with recruitment of chromatin remodelling factors of the SWI/SNF family such as Brg1, allowing access of Pol II and auxiliary transcription machinery to the transcription start site (TSS), it is often closely correlated to transcriptional activity \[[@B52]\]. Consistent with this, Pol II recruitment also exhibits ultradian rhythm-directed cyclical activity at the TSS of glucocorticoid pulse regulated genes. These cyclical changes in acetylation status of glucocorticoid-target genes, and the concomitant cycling of GR, its regulatory co-factors and Pol II at the TSS, are therefore proposed as the mechanism for temporal regulation of the gene-pulsing phenomenon associated with ultradian glucocorticoid rhythm.

Therefore the two components---the stochastic receptor and the deterministic ligand secretory pattern---appear to have evolved together to establish and maintain an optimal system of transcriptional regulation. The dynamic action is not unique to GR, extending to other transcription factors, and represents a general mechanism that permits continuous sampling of the cellular milieu \[[@B37]\]. In the case of GR, the mechanism accommodates fluctuations in hormone levels and thus can rapidly respond to physiological and pathological glucocorticoid secretory patterns. The general requirement for accessible chromatin also suggests that chromatin structure, and factors that regulate chromatin accessibility, could influence hormone sensitivity and resistance.

Repressive actions of the GR
============================

The interaction between GR and other transcription factors such as activator protein 1 (AP1) and nuclear factor kappa B (NF-κB) is known to repress gene activity through transrepression \[[@B45], [@B63; @B64; @B65]\]. GR-dependent perturbation of these pro-inflammatory factors is thought to occur through protein--protein interactions \[[@B45], [@B63], [@B64]\]. While transactivation requires GR homodimers, transrepression is mediated through GR monomers ([Fig. 2](#F2){ref-type="fig"}A) \[[@B66], [@B67]\]. Knock-out of GR from mouse renders them unviable, although interestingly, GR dimerization mutants, where GR cannot form homodimers, are viable, suggesting that transrepression by monomeric GR is sufficient for survival \[[@B68]\]. In addition, GR and AP1 can interact at composite elements, where each factor binds directly to DNA, but their proximity results in hormone-dependent modulation of AP1 action \[[@B45]\]. The interactions between GR and pro-inflammatory factors involve altered recruitment of co-regulators that directly inhibit Pol II elongation \[[@B69], [@B70]\]. Additionally, GR is a target of histone deacetylase 2 (HDAC2), resulting in de-acetylation of the receptor and preferential interactions with NF-κB \[[@B71]\].

The activity of NF-κB and AP1 are critical to numerous inflammatory conditions, including arthritis and asthma \[[@B71], [@B72]\]. In addition to transrepression, gene induction contributes to anti-inflammation by inducing the expression of immune modulators in some cell types, including the negative regulator of NF-κB, IκB-α \[[@B73], [@B74]\]. The repressive action of glucocorticoids on NF-κB and AP1 activity is therefore context dependent, with the sensitivity of glucocorticoid action dependent on the cell type and the expression and activity of pro-inflammatory proteins and co-regulators. For example, over-expression of AP1 has been shown to impair GR repression, contributing to resistance \[[@B75]\]. Furthermore, GR-dependent induction of mitogen-activated protein kinase phosphatase 1 (MKP1) and glucocorticoid-induced leucine zipper (GILZ) have anti-inflammatory actions, where disruption of their regulation alters hormone sensitivity in RA \[[@B76; @B77; @B78]\]. In respiratory conditions such as chronic obstructive pulmonary disease (COPD), reduced expression and activity of HDAC2 is associated with increased inflammatory gene expression and confers glucocorticoid resistance \[[@B71]\].

The design of receptor ligands that dissociate GR-mediated induction and repression are of much interest, with the aim of reducing side-effect profiles \[[@B79]\]. However, the mechanisms regulating GR gene induction and repression are not always clear, as GR can also induce AP1 activity \[[@B45]\]. The effect of GR on AP1 activity, whether positive or negative, is thought to depend on the composition of the AP1 complex, a multi-subunit family that can form homo- and heterodimers, and the DNA sequence of regulatory elements \[[@B80]\]. Furthermore, some side-effect profiles are related to interactions between GR and pro-inflammatory factors. Indeed, the osteoporotic side effect of glucocorticoids is thought to involve GR and AP1 interactions that inhibit osteoblast differentiation \[[@B81]\]. It is therefore unclear what role selective GR modulators will have in the clinic, although the characterization of some compounds has suggested reduced side effects, including osteoporosis \[[@B82]\]. Their clinical efficacy and safety will need to be extensively evaluated.

The distinction between GR inductive and repressive effects is a conventional, but limited, definition. Using genome-wide microarray approaches to evaluate gene expression over a long time course, the regulation of genes by GR displays complex kinetics \[[@B13]\]. In contrast to simple induction or repression, hundreds of genes undergo positive and negative regulatory phases in the presence of constant hormone ([Fig. 2](#F2){ref-type="fig"}B) \[[@B13]\]. Over hours of constant glucocorticoid exposure, induced genes can be rapidly induced to a plateau phase, transiently induced or slowly and continuously induced. Repressed genes also exhibit similar kinetics patterns, showing rapid repression that plateaus transient repression or continuous repression ([Fig. 2](#F2){ref-type="fig"}B). These classes of kinetic gene activity suggest gene-specific regulatory control by hormones. These classes are likely to be independent of hormone exposure pattern, constant or pulsatile, and independent of glucocorticoid type, endogenous or synthetic, although this has not been definitively shown. These kinetic implicate modifications to chromatin or regulatory factors, such as GR and recruited co-factors that act to modify the transcriptional output in a gene-specific manner. For instance, the acetylation of HDAC1 upon GR recruitment is thought to contribute to refractory phases in induced gene transcription \[[@B83]\]. The complexity and dynamics of glucocorticoid action are only beginning to be understood. The relevance of kinetic patterns of GR-dependent gene expression *in vivo* is not yet clear, particularly in underlying circadian and pulsatile glucocorticoid secretory modes. Nevertheless, we propose that the interplay between non-receptor transcription factors and co-regulators plays a critical role in GR action and provides a mechanism of plasticity in response the physiological and pathological signals.

Genetic and epigenetic factors in glucocorticoid sensitivity and resistance
===========================================================================

Primary generalized glucocorticoid resistance is a rare condition associated with compensatory increases in plasma ACTH and cortisol \[[@B5]\]. Patients present with features of mineralocorticoid and adrenal androgen excess due to concomitant adrenal hyperplasia and elevated adrenal steroids \[[@B84]\]. The condition results from familial or sporadic mutations of the GR gene, resulting in impaired expression, ligand binding or nuclear translocation \[[@B84]\]. Mutations in co-regulator genes might, in principle, also confer glucocorticoid resistance. Indeed, defects in the steroid receptor co-activators (SRCs) were observed in a pan-steroid resistance syndrome \[[@B85]\]. Generally, genetic mutations are unlikely to contribute to resistance affecting specific cells in common inflammatory conditions such as arthritis. Sporadic genetic mutations are more likely in rapidly dividing cells, particularly cancers. GR mutations have been associated with leukaemic cell lines associated with resistance to chemotherapeutic apoptotic effects of glucocorticoid, although their contribution to resistance in patients is contentious \[[@B86]\]. Similarly, mutations in Brg1 have been found in lung cancers, and as an important co-factor for GR action, mutations in Brg1 could contribute to glucocorticoid resistance \[[@B87]\].

Interestingly, one-third of the normal population display *in vitro* resistance to glucocorticoids and will predictably fail to respond to clinical treatment \[[@B5]\]. Single nucleotide polymorphisms (SNPs) contribute extensively to human variation and possible glucocorticoid action. Polymorphisms of the CS-binding globulin (CBG), Toll-like receptors (TLRs) and macrophage migration inhibitory factor (MIF) genes are associated with altered serum cortisol levels and glucocorticoid sensitivity \[[@B5], [@B32]\]. At the level of DNA binding, SNPs have also been shown to cause aberrant transcription factor recruitment \[[@B88]\]. Whole-genome analyses of the DNA-binding factors NF-κB and CCCTC-binding factor (CTCF) have shown that genetic variation extensively contributes to differential factor occupancy \[[@B89], [@B90]\]. These observations suggest that SNPs could alter GR-binding patterns and alter sensitivity to glucocorticoids at specific target genes. Additionally, variation in the GRE sequence modifies GR structure by acting as an allosteric modulator \[[@B91]\]. The structural difference might promote specific interactions, with co-regulators affecting GR-dependent gene regulation ([Fig. 3](#F3){ref-type="fig"}A). Therefore SNPs in GREs could modify GR action in a gene- and individual-specific fashion. F[ig.]{.smallcaps} 3Genetic and epigenetic mechanisms in GR action. (**A**) DNA is an allosteric modulator, altering the structure of the receptor when bound to DNA. SNPs (blue) at GREs (red) could alter the interactions with co-factors by influencing GR structure. The effects might contribute to gene- and individual-specific gene regulation. (**B**) DNA methylation, an epigenetic mechanism, acts to silence gene transcription by altering chromatin structure. Individual-specific experiences, such as maternal nurturing, can alter DNA methylation patterns, producing expression patterns heritable across generations. The reduction in GR expression causes resistance to hormone action in specific tissues. Cort: cortisol.

DNA methylation, an epigenetic mechanism associated with chromatin condensation and gene silencing, has been shown to modify GR gene expression \[[@B92]\]. In an experience-dependent manner, DNA methylation of the GR promoter in specific brain regions is associated with reduced GR expression levels, and consequently resistance to glucocorticoids. In rodent models, deprivation of maternal nurturing increases DNA methylation of the GR promoter in the hippocampus, resulting in trans-generational inheritance of the methylation pattern ([Fig. 3](#F3){ref-type="fig"}B) \[[@B92]\]. The observation suggests that DNA methylation is dynamic and programmable. Similarly, GR promoter methylation was observed in post-mortem hippocampi of suicide victims with a history of child abuse, suggesting interplay between methylation status and individual experience \[[@B93]\]. Experience-dependent epigenetic programming might therefore play a role in other physiological and pathological conditions. Genetic and epigenetic variation is therefore likely to contribute to glucocorticoid sensitivity, although the incidence of these variants in the general population is not fully understood.

Concluding remarks
==================

The diverse and disparate transcription networks regulated by glucocorticoids result from ubiquitous receptor expression, but cell-specific actions \[[@B11]\]. In particular, the anti-inflammatory and immunosuppressive effects are extensively exploited clinically, making glucocorticoids one of the most commonly prescribed classes of therapeutics. The chronic nature of many of the inflammatory conditions, including RA, SLE, asthma and IBD, requires long-term glucocorticoid administration. The treatment paradigms frequently result in side effects that reduce their tolerance and, not uncommonly, induce the development of glucocorticoid resistance \[[@B5]\].

Factors that contribute to the dynamics and plasticity of glucocorticoid signalling, from the patterns and levels of hormone secretion to the binding of receptor at specific DNA sequences, represent potential mechanisms regulating sensitivity and resistance. Technological advances in molecular biology such as genome-wide techniques have advanced our understanding of the molecular mechanisms of GR \[[@B11]\]. It is vital that our current understanding is translated into physiological conditions and into the clinic.

Advances in drug design and therapeutics principles should extend beyond dissociating the desired anti-inflammatory effects and reducing side effects, targeting cell-specific functions of glucocorticoids. High-throughput technologies, including genomics, proteomics and metabolomics, as well as chemical and RNA interference screening, could be employed to discover important and novel targets in glucocorticoid action in multiple cell types under different physiological and pathological backgrounds. These studies will be crucial for understanding the networks regulating glucocorticoid action, sensitivity and resistance in health and disease.
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